NCT00104091View on ClinicalTrials.gov

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

June 30, 2007

Conditions
Glioblastoma Multiforme
Interventions
DRUG

TP-38

TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00104091 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Biotech Hunter | Biotech Hunter